Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte...

Area of Science:

• Immunology
• Virology
• Hepatology

Background:

• Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and is linked to B lymphocyte disorders like mixed cryoglobulinemia and non-Hodgkin lymphoma.
• The HCV major envelope protein (HCV-E2) binds to CD81, a tetraspanin molecule present on various cell types, including B cells.

Purpose of the Study:

• To investigate the mechanism by which HCV-E2 binding to CD81 on B cells influences B cell proliferation and activation.
• To determine if in vitro findings correlate with the in vivo state of B cells in chronic hepatitis C patients and the effects of treatment.

Main Methods:

• Engagement of CD81 on human B cells using a combination of HCV-E2 and an anti-CD81 monoclonal antibody (mAb).
• Analysis of JNK pathway activation and B cell proliferation, specifically differentiating between naive (CD27-) and memory (CD27+) B cell subsets.
• Assessment of B cell activation markers in patients with chronic hepatitis C before and after interferon (IFN) therapy.

Main Results:

• HCV-E2 and anti-CD81 mAb co-engagement activated the JNK pathway and promoted preferential proliferation of naive B cells.
• B lymphocytes from most chronic hepatitis C patients exhibited heightened activation, with naive cells showing higher activation marker levels than memory cells.
• IFN therapy leading to HCV eradication resulted in the normalization of B cell activation marker expression.

Conclusions:

• CD81-mediated activation of B cells in vitro mimics the effects of HCV binding to B cells in vivo.
• Polyclonal proliferation of naive B lymphocytes is proposed as a critical initiating factor in the pathogenesis of HCV-associated B lymphocyte disorders.